Methods. We examined 24 patients with CRPS type I using standardized Quantitative Sensory Testing on the affected hand and the contralateral hand at baseline and 6 months following treatment. Somatosensory evoked potentials after single and paired-pulse stimulation of the median nerve were performed to assess the paired-pulse suppression (n 5 19) . Treatment response at follow-up was defined as pain relief > 30% and improved hand function. Statistics: Wilcoxon test, Pearson correlation.
Results. At baseline, similar to previous studies, the pressure pain threshold (PPT) was significantly decreased and the pain response to repeated pinprick stimuli was significantly increased, while all detection thresholds were within the normal range without any difference between the later treatment
Introduction
The complex regional pain syndrome (CRPS) is a disabling disease characterized by sensory, motor, and autonomic dysfunction [1] , joint impairment, and complex central alterations [2] , leading to long-term pain, functional impairment, and disability in >50% of the cases [3, 4] . The pressure hyperalgesia, suggested to be a sign of peripheral sensitization [5] , has been demonstrated as the most prominent sensory abnormality, assessed both over muscles as well as over the metacarpophalangeal and the proximal interphalangeal joints [6, 7] . In line with that, in the early stage of the disease peripheral inflammation seems to play an important role [9] , whereas we have shown that the proinflammatory state diminishes throughout the course of the disease, independent of the treatment outcome [10] . However, until now it is unclear how the finding of pressure hyperalgesia, which is one of the impeding findings in CRPS patients, changes over the course of the disease and what its relation to treatment outcome is. Additionally, complex central nervous system dysfunction has been demonstrated, including decreased cortical representation of the affected hand with impaired tactile spatial acuity without peripheral nerve lesion [11] , distorted body representation [12] [13] [14] [15] , neglect-like symptoms [16] [17] [18] [19] [20] , and bilateral cortical hyperexcitability in the motor [21] [22] [23] [24] [25] and somatosensory systems [26] .
Only a few studies have examined the sensory abnormalities in CRPS over the course of the disease and how the abnormalities relate to treatment effects. Pain reduction was accompanied by restoration of the impaired tactile discrimination 1-6 months after treatment [27] and the area of mechanical hyperalgesia decreased 1 year after treatment [28] , both suggesting recovery from the maladaptive cortical reorganization.
Furthermore, lower pressure pain thresholds over the ulnar styloid were associated with increased disease progression after 8 years [29] . However, there are no prospective studies investigating the changes of the complete sensory profile in CRPS in relation to the inflammatory state and central dysfunction (e.g., pairedpulse suppression of somatosensory evoked potentials (SEP) as a measure of cortical excitability).
The present analysis investigated somatosensory changes in patients with CRPS participating in a multidimensional study (results partly reported in [10, 26] ) after 6 months of individualized treatment in order to: 1) assess the changes of the somatosensory function using standardized quantitative sensory testing (QST) and paired-pulse suppression of SEPs (primary endpoint); and 2) verify differences in the sensory profile depending on the treatment response (defined by pain reduction and function recovery) before and after a 6-month treatment (secondary endpoints).
Methods

Subjects
After approval by the local Ethic Committee of the RuhrUniversity Bochum (Germany), 28 patients (righthanded: n ¼ 25; left-handed: n ¼ 2; both-handed: n ¼ 1, assessed by the Edinburgh Handedness Inventory [30] ) with CRPS type I of the upper extremity (without nerve lesion) were prospectively recruited from the Department of Pain Medicine (BG University Hospital Bergmannsheil GmbH, Ruhr-University Bochum, Germany) and enrolled in a single-center longitudinal study (Table 1 ). All patients fulfilled the Budapest criteria for research [1] and presented with an enhanced bone metabolism in the late phase of a 99m-technetium-triple-phase-bone-scintigraphy [8] . Nerve lesions were excluded by experienced clinicians based on the clinical examination, electroneurography, and N20-latencies of the median nerve somatosensory evoked potential (inhouse cut-off value of 22.9 ms) [10] as well as severe sensory loss in the QST according to the protocol of the German Research Network on Neuropathic Pain (DFNS) [31, 32] .
Data from the same patients' cohort on paired-pulse suppression of somatosensory evoked potentials at baseline and on cytokine changes over the course of the disease have been recently reported elsewhere [10, 26] .
Study Design
QST was performed in accordance with the standardized comprehensive DFNS protocol [31, 32] . Somatosensory evoked potentials after single and after paired-pulse stimulation of the median nerve were performed to assess the paired-pulse suppression (PPS). Additionally, current and average pain intensity in the last 4 weeks were assessed on the NRS 0-10 Enax-Krumova et al.
(numerical rating scale, 0 ¼ no pain, 10 ¼ maximal pain imaginable). Medication intake, origin of illness, and results of the clinical examination were also recorded. The global joint impairment of the affected hand was assessed, as previously described [10] measuring the range of motion (ROM) of the wrist joint, the metacarpophalangeal joint of the second and the third finger, and was defined as "unimpaired" if the ROM of all three joints was !0.8, "impaired" if the ROM of one of the joints was 0.4-0.8, and "strongly impaired" if the ROM of at least one of the three joints was 0.4.
All measures were assessed at referral to the pain clinic prior to treatment and 6 months later. In the present study the treatment could not be standardized, but was symptom-based, decided in detail by the treating physician in charge. The multimodal treatment was performed according to the good clinical practice, with focus on certain aspects depending on the specific needs of the patients. In general, it comprised pharmacotherapy (opioids or other analgesics, antidepressants or anticonvulsants, as well as anti-inflammatory treatment by corticosteroids and non-steroidal anti-inflammatory drugs if clinical signs of inflammation like edema, redness, or joint stiffness were present), positional therapy, sensorimotor training (occupational treatment, physiotherapy) as well as psychological treatment and, if indicated, invasive treatment by sympathetic blocks (see Table 2 ) [27, 33] . For all study participants the treatment lasted continuously during the 6 months, whereas the first 2-3 weeks it was during inpatient stay, and later on it was outpatient treatment.
A positive treatment response was defined as >30% pain relief 6 months after multimodal symptom-based treatment, in comparison to the baseline ratings, calculated based on the average pain intensity in the last 4 weeks, reported on the NRS 0-10. Additionally, changes of the global hand function (joint impairment including finger-palm distance and range of motion of the wrist) were assessed at follow-up and were categorized as "healed," ''improved,'' ''unchanged,'' or "worsened," as previously described in detail [10] .
Quantitative Sensory Testing
The standardized QST battery according to the DFNS protocol [31] assesses the following parameters: thermal 64, 128, 256, and 512 mN (flat contact area of 0.2 mm diameter); stimulus/response-functions for pinprick sensitivity (mechanical pain sensitivity, MPS), using the same set of pinpricks as for the MPT, which were rated on a '0-100' numerical rating scale ('0' indicating ''no pain,'' and '100' indicating ''most intense pain imaginable''); dynamic mechanical allodynia (DMA) using a cotton wool, Q-tip, and a standardized brush (Somedic, Sweden) as moving innocuous stimuli, which were applied in a balanced manner during the assessment of MPS and were rated on a '0-100' numerical rating scale ('0' indicating ''no pain,'' and '100' indicating ''most intense pain imaginable''); pain summation to repetitive pinprick stimuli (wind-up ratio, WUR), assessed as a ratio between a single stimulus of 256 mN and a series of 10 repetitive applications of the same stimulus intensity in a frequency of 1/s.
All measurements were performed at the certified QST laboratory of the BG University Hospital Bergmannsheil GmbH. All sensory tests were performed at the dorsal hand in side-to-side comparison, always starting with the unaffected side. Results were evaluated in comparison with the published reference norm data and considering side-to-side differences [31, 32] .
Paired-Pulse Stimulation and SEP Recordings
Somatosensory evoked potentials after single and after paired-pulse stimulation of the median nerve were performed to assess the paired-pulse suppression, as described in detail in [26] . We used a paired-pulse protocol consisting of innocuous paired electrical stimulation of the median nerve with a stimulus onset asynchrony (SOA) of 30 msec in combination with recordings of somatosensory evoked potentials (SEP). Nerve stimulation (pulse duration 0.2 msec, repetitive rate of the paired stimuli 3 Hz) was performed using a block electrode placed on the wrist of the affected and unaffected hand of patients. Subjects had to report a prickling sensation in the thumb, index, and middle finger of the stimulated hand to verify correct positioning of the stimulating block electrode. As a rule, the stimulation intensity was individually adjusted to the 200% of individual sensory thresholds. The stimulation intensity induced a small muscular twitch in the thenar muscles in all patients. During median nerve stimulation and SEP recordings, subjects were seated in a comfortable chair and were instructed to relax but stay awake with eyes closed. SEP signals were amplified and filtered using a BrainAmp magnetic resonance amplifier (BrainProducts GmbH, Gilching, Germany) and digitized in a PCrunning BrainVision Recorder software package (BrainProducts GmbH) (sampling rate of 5 kHz, band-pass filtering between 10 and 1000 Hz). Paired-pulse SEP were recorded using a threeelectrode array. Two electrodes (Cp3 and Cp4) were located over the left and right primary somatosensory cortex (S1) according to the international 10-20 system [34] . A reference electrode was placed over the midfront (FZ) position. Single-pulse SEP (sp-SEP) of both hands was recorded additionally using the same setup as for the paired-pulse SEP (pp-SEP). A total of 800 stimulus-related epochs from 30 before to 150 ms after the (first) stimulus was recorded and averaged for single (n ¼ 200) and paired (n ¼ 200) stimuli on each side. The sequence of single and paired stimulation as well as stimulus presentation on affected and unaffected side was pseudorandomized to avoid bias effects.
All measurements were performed at the neurophysiology lab in the Department of Neurology of the BG University Hospital Bergmannsheil GmbH.
We analyzed peak-to-peak amplitudes of the cortical N20-P25 response component for the first and second paired-pulse stimulus. To assess "true" paired-pulse interaction, linear superposition effects had to be factored out by subtracting the response to the single-pulse stimulation from the paired-pulse stimulation trace. We analyzed the second pp-SEP amplitude after linear subtraction of the sp-SEP (A2s) and referred it to the first pp-SEP amplitude before linear subtraction (A1). PPS was expressed as a ratio (A2s/A1) of the amplitudes of the second (A2s) and the first (A1) peak (Supplementary Figure 1) .
Statistical Analysis
According to the DFNS protocol, all QST data except the data for paradoxical heat sensation, cold pain thresholds, heat pain thresholds, and vibration detection were transformed logarithmically before further analysis using z-transformation [31, 32] . Due to the unequal number of patients in the group of later treatment responders and non-responders all data are represented as median and range. QST data were compared with the published normative data for the upper extremity [32] . The QST parameters of every single subject were transformed into Z-values based on the previously published reference data of the DFNS [32] , using the following term: Z-value ¼ (Mean single patient -Mean reference data )/SD reference data A z-value of 0 6 1.96 represents the range including 95% of the healthy subject data at baseline. Positive z-values indicate a gain of function (more sensitive, i.e., hyperesthesia, hyperalgesia) for the tested stimuli, whereas negative z-scores indicate a loss of function (less sensitive, i.e., hypoesthesia, hypoalgesia). A z-score of zero represents a value corresponding to the mean of the healthy subjects at baseline.
All statistical calculations were performed using IBM SPSS Statistics 19. Mann-Whitney-U test was conducted for comparison of metric variables (e.g., age, duration of disease, pain intensity, and sensory data) between the groups of later treatment responders and non-responders. Fisher's exact test was used to analyze non-parametric data. Wilcoxon-Test was used to compare paired metric variables between the measurements before treatment and 6 months later within the whole group of patients with CRPS as well as separately for the treatment responders and non-responders. BlandAltman analysis was performed to visualize intraindividual differences between the pressure pain threshold at baseline and at follow-up. Pearson correlation coefficient was used to test for significant correlations between SEP parameters and the extent of pain relief as well as between SEP parameters and PPT, after verifying normal distribution of the data using the KolmogorovSmirnov test. Additionally, we have analyzed the QST parameters on the contralateral clinically unaffected hand compared with a virtual reference group based on published mean and standard deviation of the reference data after z-transformation, an approach, which we have previously introduced [32] . The virtual control group approach avoids cumbersome selection procedures, obeys the principle of equal group size and is characterized by a mean 6 SD of 0 6 1 with the same number as in the patient group [32] . We used the internet-based statistical software Simple Interactive Statistical Analysis (SISA, URL: http://www.quantitative skills.com/sisa/), as previously suggested [32] .
P values of <0.05 were regarded as statistically significant, P values of <0.01 -as highly significant.
Results
Clinical Data and Treatment Response
Four of the patients were lost to follow-up. Thus, clinical features and QST data are reported for 24 patients with CRPS I (15 female) aged 25 to 70 years (mean age: 52.4 6 10.1), who underwent the whole longitudinal study. The disease duration at study inclusion ranged between 1 and 16 months (mean duration: 4.8 6 3.5 months).
Clinical data at baseline and after treatment are reported in Table 1 and Table 2 . According to the definition of treatment response (>30% pain relief), 17 patients were classified as responders and seven as non-responders. Both groups did not differ in their disease duration or pain intensity at baseline. The median pain relief for the current and average pain intensity in the group of treatment responder was 61% and 67%, respectively, whereas in the group of non-responders it was 14% and 0%, respectively. The global hand function was classified as healed in six of the responders and in only one of the non-responders, four responders and two non-responders improved, whereas six responders and three non-responders remained unchanged in their global hand function and one patient from each of the groups worsened. Eight of the responders and only one of the non-responders achieved a recovery of their working ability after 6 months of treatment ( Table 2 ).
The number of patients who did not tolerate the examination of the somatosensory evoked potentials already at baseline was significantly higher in the group of the later non-responders (n ¼ 4 vs n ¼ 1 in the group of responders, Fisher's exact test, P ¼ 0.014). Thus, PPS data and their correlation to PPT are reported from 19 patients with CRPS I, 16 of them were classified as responders.
Neither the assessed clinical parameters nor the performed treatment were able to serve as predictors for future treatment response.
Sensory Profiles at Baseline
Before treatment, the PPT was significantly lower and the WUR was significantly higher on the affected side compared with the contralateral side. The thermal and mechanical detection thresholds were within the normal range, except for a significantly increased TSL on the affected side compared with contralateral.
Before treatment, the sensory profiles on the affected side of the later treatment responders were similar to the sensory profiles of the later treatment nonresponders without significant differences, except for a significantly higher MDT in the later responder group ( Figure 1B vs 1C , post-hoc power 81%), though the post-hoc power calculation revealed power between 3% and 54% for the rest of the QST parameters.
Comparing the contralateral clinically unaffected hand at baseline to the published reference data [32] , there was a significant difference for CDT (indicating loss of function on the contralateral clinically unaffected side) and for MPT (indicating gain of function on the contralateral clinically unaffected side).
Sensory Profiles at Follow-Up
Almost all patients had a higher pressure pain threshold 6 months after treatment than at baseline (Supplementary Figure 2) . In the group of treatment responders we found a characteristic significant increase of the PPT 6 months after successful treatment resulting in pain relief >30% ( Figure 1B) . In contrast, the increased PPT remained unchanged in the group of nonresponders 6 months after treatment ( Figure 1C ). The number of abnormal values in the subgroup of treatment responders compared with the previously published reference data [32] decreased for PPT from 41% to 12% (considering also the side-to-side difference resp. from 76% to 59%), whereas in the subgroup of treatment non-responders the amount of abnormal values remained nearly unchanged (72% at T1 vs 57% at T2) (Supplementary Figure 3) . Two of the seven nonresponders and only one of the 17 responders presented with even lower pressure pain thresholds after 6 months (Supplementary Figure 2) . Additionally, the number of patients with decreased mechanical pain threshold increased from two out of seven at baseline to five out of seven at follow-up (Supplementary Figure 3) , whereas in the group of treatment responders it even decreased from eight out of 14 at baseline to six out of Enax-Krumova et al. Figure 1 Sensory profiles on the affected side at baseline compared with 6 months later in (A) the whole patients' sample, and in the subgroups of (B) responders and (C) non-responders. T1: at baseline, T2: after 6 months of multimodal treatment cold detection threshold (CDT). WDT ¼ warm detection threshold; TSL ¼ thermal sensory limen; CPT ¼ cold pain threshold; HPT ¼ heat pain threshold; PPT ¼ pressure pain threshold; MPT ¼ mechanical pain threshold; MPS ¼ mechanical pain sensitivity; WUR ¼ wind-up ratio; MDT ¼ mechanical detection threshold; VDT ¼ vibration detection threshold.
14 at follow-up. The detection thresholds remained unchanged or increased slightly (mostly in the group of treatment non-responders).
Comparing the contralateral clinically unaffected hand at follow-up to the reference data, there was a significant difference for VDT (indicating loss of function on the contralateral clinically unaffected side) and for MPT (indicating gain of function on the contralateral clinically unaffected side).
Paired-Pulse Suppression
We have recently reported significantly reduced pairedpulse suppression in the very same CRPS patients as analyzed in the recent study, compared with healthy subjects (mean amplitude ratio 6 standard error; in the control group: 0.72 6 0.05, data from [26] ) and patients with non-neuropathic upper limb pain [26] .
In the whole group of CRPS patients and within the subgroup of responders, there was no difference between the amplitude ratios of the SEP at baseline (data from [26] ) and at follow-up neither on the patients' affected hand nor on the clinically non-affected hand. The difference between both hands at follow-up was also not significant (Table 3 ). The small number of patients with SEP data in the group of non-responders (n ¼ 3) did not allow separate statistical analysis of this subgroup. The amplitude ratios neither at baseline nor at follow-up or their difference (T2ÀT1) correlated with the extent of pain relief (neither regarding the current nor regarding the average pain intensity).
Correlation Between the Pressure Pain Threshold and Paired-Pulse Suppression
There was no correlation between PPS and PPT (z-value) at baseline (r ¼ 0.28, P ¼ 0.26, Figure 2A) , whereas there was a low to moderate correlation at follow-up (r ¼ 0.49, P < 0.05) and a low PPT was associated with an impaired PPS ( Figure 2B ). However, when analyzing only the treatment responders (n ¼ 16), the correlation missed the significance level (r ¼ 0.44, P ¼ 0.09).
Discussion
This longitudinal study (as part of a multidimensional study) provides the first evidence for specific changes in the sensory profile of patients with CRPS after a 6-month multimodal individualized treatment. The most prominent sensory abnormality in CRPS patients at baseline was a decreased pressure pain threshold assessed over muscles, indicating of pressure hyperalgesia [5] . Interestingly, the majority of QST parameters remained nearly unchanged at follow-up, with the exception of the pressure pain threshold. After successful treatment, pressure hyperalgesia over muscles decreased, whereas it remained unchanged in nonresponders. The initially altered paired-pulse suppression measured bilaterally (previously reported by our group in the same patients' cohort compared with healthy subjects and patients with non-neuropathic pain [26] ), persisted also at follow-up; however, the pressure hyperalgesia and the PPS correlated only at follow-up, where low PPT were associated with impaired PPS.
Our finding of pressure hyperalgesia over muscles is in accordance with previous studies on CRPS [6, 7, 35, 36] , with 75% of the patients presenting it, similarly to previous results (67%) in a larger cohort of over 300 patients with CRPS [6] . Interestingly, the pressure hyperalgesia over the metacarpophalangeal and the proximal interphalangeal joints was more specific for CRPS than that over muscles and correlated with the nucleotid enhancement in the late phase of triple-phase bone scintigraphy (TPBS) [7] . The region of interest values for the carpal bones in Phase III of TPBS of the affected hand have been previously demonstrated to significantly correlate with the serum concentration of osteoprotegerin, a biomarker for bone turnover [37] . The abovementioned changes are suggested to represent peripheral Figure 2 Correlation analysis between the paired-pulse suppression (assessed by the quotient A2s/A1) and the pressure pain threshold (PPT, z-value) at baseline (A) with r ¼ 0.28, (P ¼ 0.26) and at follow-up (B) with r ¼ 0.49 (P < 0.05), indicating that at follow-up, a lower PPT (also in the group of responders) was associated with impaired paired-pulse suppression, which was significant only at follow-up.
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inflammatory mechanisms, which seem to play an important role at least in the early stages of the disease [9, 38] . This was also supported by a proinflammatory cytokine profile at baseline in our sample, characterized by bilaterally increased protein levels of TNF-alpha and MIP-1beta and decreased protein levels of IL-1RA in CRPS I compared with non-CRPS patients, discussed elsewhere [26] . Interestingly, the PPT at baseline and at follow-up correlated neither with the local protein levels of TNF-alpha (as a proinflammatory cytokine) nor of IL1ra (as anti-inflammatory cytokine), or with the quotient of TNF-alpha and IL-1ra (data not shown), suggesting that the generation of the pressure hyperalgesia in CRPS is not solely based on inflammatory mechanisms.
In a previous study, decreased PPT have been demonstrated to be the only nociceptive parameter that related to measures of motor function in patients with CRPS type I [36] . This corresponds to our results, which show a stronger pressure hyperalgesia and a smaller range of motion in the wrist in non-responders than responders at follow-up. The significant improvement of the pressure hyperalgesia in the group of responders was achieved after 6 months of multimodal individualized analgesic treatment and was accompanied also by improvement of functional parameters like the joint impairment, range of motion of the wrist, and the global hand function (see Table 2 ). In contrast, our previous study assessing short-term effects of coxibe treatment in CRPS patients found changes neither in the pain intensity nor in the PPT [35] . The persistence of pressure hyperalgesia at follow-up in the group of nonresponders may relate to a shift from peripheral to central mechanisms over the course of the disease. This is also supported by our recently reported blister fluid analysis on the same patient cohort showing that in patients with CRPS the proinflammatory cytokine profile diminished over time, independent of the treatment outcome [10] . Some studies examining the pressure hyperalgesia in other chronic pain states without nerve lesion have discussed an up-regulation of the central processing of nociceptive stimuli from the muscles in chronic pain [39, 40] . Also in CRPS a widespread muscle hyperalgesia has been reported as an indicator of a disturbance in central pain processing, attributed to impaired endogenous pain control [41] .
Additional evidence that central mechanisms likely play a role in the persistence of pressure hyperalgesia at follow-up come from the significant correlation we found between the PPT and PPS after sensory stimulation of the median nerve (based mostly on the treatment responders), with lower PPT associated with impaired PPS. Impaired PPS was demonstrated to indicate maladaptive central nervous changes, specifically in CRPS patients, who show bilaterally impaired inhibition both in the sensory [26] and the motor systems [24] . This is suggested to be one aspect of sensorimotor cortical changes in patients with CRPS, namely the altered excitability of cortical neurons [26] . Thus, our results suggest that the abnormal excitability of cortical neurons tends to parallel the improvement of the pressure hyperalgesia, although there were no significant differences between the SEP amplitude ratios at baseline and at follow-up. This finding is particularly interesting for several reasons. On the one hand, cortical excitability in CRPS patients showed no differences between the affected and contralateral sides at baseline, in contrast to findings for the hand representation in imaging studies [21] . On the other hand, we demonstrated in former studies a normalization of the representation of the affected hand both after long-term sensory-motor training and within a short period of time after successful analgesic treatment [27, 33] , whereas in the present study, the bilaterally impaired PPS remained unchanged after 6 months of treatment, independent from the magnitude of the pain relief. This finding once more suggests that there are two different central mechanisms that seem to be more or less independently impaired in CRPS patients. While the decreased size of cortical representation of the affected hand may result from the CRPS itself, as it correlates with pain intensities and treatment outcome, the bilaterally impaired PPS may be a more useful trait marker. However, the conclusion that it might even be a sign for a predisposition toward developing CRPS is to be regarded with caution, given that the individual paired-pulse ratios, both at baseline and at follow-up, showed substantial variance and given that there was considerable individual overlap between patients and control subjects [26] . Additionally, there was no correlation between the severity of cortical disinhibition and the clinical signs [26] .
Unexpectedly, the tactile detection threshold at baseline was significantly higher in the later responder group with 29% of patients having abnormal values vs 14% in the later non-responder group (including side-to side differences). In contrast, recent pharmacological studies on painful neuropathy demonstrated that stronger sensory loss was associated with less pain relief than in the subgroup with an irritable nociceptor phenotype and predominant gain of function [42, 43] . In CRPS type I (without nerve lesion) increased two-point discrimination thresholds may be a sign for maladaptive central changes with shrinkage of the cortical maps in the contralateral somatosensory cortex, which was shown to be reversible after successful pain treatment [27, 28] . Thus, the present results support the hypothesis that the impaired tactile acuity does not represent a negative predictor of poor treatment outcome in CRPS per se.
Unfortunately, similar to an analysis of the cytokine profiles of the same patients' sample (published in [10]) we were not able to identify biomarkers predicting the treatment response based on the sensory profiles or based on the results of the paired-pulse suppression. Though, this is in agreement also with previous studies. For example, there was no relationship between the severity of the symptoms of CRPS in the course of the disease and the results of enhanced bone metabolism in the triple-phase bone scintigraphy, the sensitivity of the triple-phase bone scintigraphy declined 5 months after disease onset independently from the severity of CRPS symptoms [8] . Also, there was no correlation between the osteoprotegerin concentration and the CRPS symptoms in different disease phases (<12 weeks and !12 weeks) [37] . Thus, it seems that the extent of the inflammation in the early stages of the disease is not predictive of the course of the disease or the treatment outcome and further longitudinal studies focusing on different aspects of the central involvement in CRPS already in the early stages are needed to explore for any biomarkers predicting the treatment response.
There are several limitations of the present study. First, the unequal number between both subgroups of treatment responders (n ¼ 17) and non-responders (n ¼ 7) results in restrictions regarding the statistical analysis for comparison of both groups. This limitation is difficult to compensate for in a longitudinal study design with a single-center. Additionally, due to the small sample size, our study may be underpowered to detect slight differences between the responders and non-responders or slight changes of the sensory parameters after treatment. Future multicenter studies are required, which include higher numbers of patients to substantiate our results. Also, based on our results at the follow-up after 6 months of treatment we cannot exclude any later changes in the non-responders group, as, for example, the area of mechanical hyperalgesia, a sign for central sensitization, was reported to decrease after 1 year of treatment [28, 44] . It cannot be excluded that the kind of treatment potentially interferes with the sensory changes and/or the treatment response. However, in case of CRPS it is extremely hard to focus on one kind of treatment due to the need of multimodal therapy. Also due to the high interindividual variety of the presented symptoms in patients with CRPS, it is difficult to perform exactly the same treatment in all study participants. Another limitation of the present study is that five patients (four non-responders, one responder) did not tolerate the examination of the somatosensory evoked potentials. Thus, a statistical comparison between both subgroups regarding the PPS data was impossible. For approximate analysis we therefore calculated a correlation between the PPT and PPS within the subjects with data on the somatosensory evoked potentials (n ¼ 19; however, 16 of the 19 classified as treatment responders). Thus, we can only indirectly conclude that central maladaptive changes play a role in the subgroup of patients without sufficient treatment response and persisting pressure hyperalgesia. Although we found a significant correlation between PPS and PPT at followup for the complete study group, this correlation fails to be significant in the response group. However, as both correlation coefficients are almost equal in both cases (0.49 and 0.44, respectively), this demonstrates that terms of significance have to be handled with care when dealing with small sample sizes. Future studies with bigger study groups and a balanced number of treatment responders and non-responders and also including the examination of central changes by imaging techniques are needed to confirm our results and might even produce more pronounced results.
In conclusion, in patients with CRPS the sensory profile remained mostly unchanged and the most distinct finding was the pressure hyperalgesia, but successful treatment led to its normalization within 6 months. Thus, the pressure hyperalgesia could be a promising outcome criterion in interventional treatment studies in CRPS patients. Further encouragement for its clinical relevance comes from the association found with impaired pairedpulse suppression over the course of the disease, which is suggested to represent maladaptive central nervous changes in CRPS. Further studies should examine the exact reasons for the interaction between peripheral and central mechanisms to be able to identify predispositions for patients who are resistant to the current treatment approach.
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